As we previously reported, the U.S. Department of Justice (“DOJ”) filed a lawsuit under the Anti-Kickback Statute against Regeneron Pharmaceuticals in the District of Massachusetts regarding Regeneron ...
Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising ...
The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for its top-selling eye drug Eylea. In a lawsuit filed in U.S.
Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals (REGN.O), opens new tab on Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease ...
With Eylea biosimilar competition creeping in and Roche’s Vabsymo jockeying for market share in key indications, Regeneron is racing to carve out a new market for the high-dose version of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results